Standards Programs
"PPTA's voluntary standards program provides global leadership for the plasma protein industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient. The standards program will be transparent, credible, innovative and responsive to stakeholder and industry needs."
- Mission Statement, PPTA Voluntary Standards Program
 |
 |
|
Human plasma is processed and used in dozens of different lifesaving plasma protein therapies. People who use these therapies manufactured from human plasma rely on the generous donations made by committed individuals. To further improve the quality and safety of source plasma, PPTA developed the International Quality Plasma Program (IQPP).
IQPP provides independent, third-party evaluation and recognition of a center's adherence to global industry standards for source plasma.
Learn more
|
People around the world depend on therapies derived from human plasma proteins to treat bleeding disorders, primary immune deficiencies, Alpha-1 antitrypsin disease and certain neurological conditions. Plasma protein therapies are also used in emergency and surgical medicine.
Safety of plasma protein therapies is the top priority of the plasma fractionation industry. PPTA, on behalf of its industry members, supports efforts by regulatory authorities to establish minimum requirements to ensure the safety of these products.
Learn more
|
